Company
Headquarters: Beijing, China
Employees: 952
CN¥6.20 Billion
CNY as of Jan. 1, 2025
US$848.9 Million
| Company | Market Cap (USD) |
|---|---|
| Novo Nordisk | $622.07 B |
| Vertex Pharmaceuticals Incorporated | $113.24 B |
| CSL Limited | $95.75 B |
| Regeneron Pharmaceuticals, Inc. | $76.33 B |
| Marinomed Biotech AG | $56.13 B |
| Company | Market Cap (USD) |
|---|---|
| Lilly | $689.42 B |
| Novo Nordisk | $622.07 B |
| UnitedHealth Group | $487.54 B |
| Johnson & Johnson | $353.05 B |
| AbbVie | $301.60 B |
Beijing Hotgen Biotech Co., Ltd. engages in the research, development, manufacture, and sale of medical and public safety inspection products of in-vitro diagnostic products in the field of biomedicine. It offers drug detection, CDC, Up-conversion luminescence technology, colloidal gold, CLIA, sugar capture, microfluidic, and gene detection products for testing of intestinal microorganisms, gastrointestinal foodborne infections, insect-borne diseases, respiratory pathogens, infectious diseases, Ebola virus antigen, biological warfare agents, microorganisms, and mycotoxins. The company was founded in 2005 and is based in Beijing, China.
Beijing Hotgen Biotech Co. Ltd has the following listings and related stock indices.
Stock: SSE: 688068 wb_incandescent